Metyrapone as Additive Treatment in Major Depression

• Status: Completed
• Trial end date: 2001-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test whether metyrapone is an effective and safe augmenting agent in the treatment of major depression.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universitätsklinikum Hamburg-Eppendorf
• Treatments: Metyrapone

Criteria

Inclusion Criteria:

• Diagnosis of major depressive disorder; single or recurrent according to DSM-IV criteria (296.2 or 296.3)

• A minimum baseline Hamilton score of 18 points on the Hamilton Rating Scale for Depression (HamD; 21-item version)

• Age from 18 to 75 years

• A drug free period of at least 5 days from antidepressants, antipsychotics, mood stabilizers and all other medications except for mild antihypertensive agents

• A negative urinary drug screening diagnosis

Exclusion Criteria:

• A current DSM-IV diagnosis for other axis I psychiatric disorders

• Serious medical conditions, especially those associated with adrenal insufficiency

• Pregnancy, nursing or refusal to use a reliable method of birth control in women.

Participants were randomly assigned to a study group if they met these criteria.